Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.22

+8.3%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$84.78M
EPS-0.6700
P/E Ratio-3.31
Earnings Date08/05/2026

sera

Research Development Expenses

Last Annual Value

13.17M

3-Year CAGR

-3%

5-Year CAGR

11%

10-Year CAGR

3%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of research-development-expenses

SERA · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.17M
-4.7%3.6%N/A 
13.60M
2.0%6.8%N/A
3.37M
-11.4%-4.8%2.6%
31.86M
21.5%53.0%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
13.56M
7.7%32.5%N/A
25.58M
-3.6%-11.4%10.3%
15.90M
19.6%25.9%10.8%
39.38M
-3.9%27.0%25.9%
23.72M
-11.1%3.5%15.4%
5.68B
821.7%260.7%N/A
20.53M
97.6%6.2%15.2%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.22, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.22